Blog
RSS FeedPosted by Michael Wonder on 23 Jul 2020
CADTH publishes final recommendation for Mayzent
23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple ...
Posted by Michael Wonder on 20 Jul 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. ...
Posted by Michael Wonder on 20 Jul 2020
CADTH publishes final recommendation for Stelara
20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients ...
Posted by Michael Wonder on 14 Jul 2020
Dupixent (dupilumab) receives positive recommendation from INESSS for the treatment of moderate to severe atopic dermatitis in adolescents
14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec ...
Posted by Michael Wonder on 03 Jun 2020
CADTH publishes final recommendation for Crysvita
1 June 2020 - CADTH has completed its assessment of burosumab for the treatment of patients with X-linked hypophosphatemia. ...
Posted by Michael Wonder on 25 May 2020
CADTH sees green for Beovu
25 May 2020 - CADTH has published its final recommendation for Novartis' Beovu. ...
Posted by Michael Wonder on 21 May 2020
CADTH posts final recommendation for Entyvio
21 May 2020 - CADTH has completed its consideration of subcutaneous vedolizumab for the treatment of adult patients with moderately to ...
Posted by Michael Wonder on 18 Feb 2020
CEADM applauds CADTH's decision to recommend an innovative depression medication for publicly-funded drug plans in Canada
18 February 2020 - Canadians for Equal Access to Depression Medication (CEADM) applauds the CADTH's recent decision recommending that the ...
Posted by Michael Wonder on 28 Nov 2019
Takhzyro (lanadelumab injection) receives positive recommendation from CADTH's Canadian Drug Expert Committee for the routine prevention of hereditary angioedema attacks
22 November 2019 - The positive recommendation is supported by the recently released findings of the Phase 3 Help Study™ Open-Label ...
Posted by Michael Wonder on 23 Nov 2019
Santen receives CADTH Canadian Drug Expert Committee reimbursement recommendation for Verkazia (cyclosporin 0.1%) eye drops
22 November 2019 - Santen Canada announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee ...
Posted by Michael Wonder on 01 Aug 2019
Proposal to enhance the transparency of CADTH’s review reports and recommendations
31 July 2019 - CADTH is committed to increasing the transparency of its health technology assessment processes. ...
Posted by Michael Wonder on 23 Apr 2019
Additional embargo period following revised CDEC recommendations
17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an ...
Posted by Michael Wonder on 03 Mar 2019
Biogen responds to CADTH’s updated recommendation regarding coverage for Spinraza
1 March 2019 - CADTH has expanded their recommendations for public reimbursement for SMA patients. ...
Posted by Michael Wonder on 29 Oct 2018
Mavenclad (cladribine tablets) receives positive CADTH Canadian Drug Expert Committee recommendation
29 October 2018 - Funding recommendation marks an important step to provide access to this innovative new oral treatment for Canadians ...
Posted by Michael Wonder on 08 Oct 2018
Committee recommends against funding $250,000-a-year Orkambi cystic fibrosis drug
4 October 2018 - Canadian governments should not pay for a $250,000-a-year cystic fibrosis medication because it is not clear ...